Title :

Allogeneic stem cell transplantation for patients with acute myeloid leukemia (AML) in second complete remission (CR2) transplanted from unrelated donors with post-transplant cyclophosphamide (PTCy). A study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.

Author(s) :

Nagler, Arnon [Auteur]
Chaim Sheba Medical Center
Labopin, Myriam [Auteur]
CHU Saint-Antoine [AP-HP]
Swoboda, Ryszard [Auteur]
Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology [MCMCC]
Kulagin, Alexander [Auteur]
Pavlov First Saint Petersburg State Medical University [St. Petersburg]
Labussière-Wallet, Hélène [Auteur]
Centre Hospitalier Lyon Sud [CHU - HCL] [CHLS]
Rovira, Montserrat [Auteur]
University of Barcelona
Blaise, Didier [Auteur]
Centre de Recherche en Cancérologie de Marseille [CRCM]
Vydra, Jan [Auteur]
Yakoub-Agha, Ibrahim [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Choi, Goda [Auteur]
University Medical Center Groningen [Groningen] [UMCG]
Reményi, Péter [Auteur]
Dél-pesti Centrumkórház - Országos Hematológiai és Infektológiai Intézet [Budapest, Hungary]
Koc, Yener [Auteur]
Sanz, Jaime [Auteur]
Hospital Universitari i Politècnic La Fe = University and Polytechnic Hospital La Fe
Ciceri, Fabio [Auteur]
Ospedale San Raffaele
Mohty, Mohamad [Auteur]
CHU Saint-Antoine [AP-HP]

Journal title :

Bone Marrow Transplantation

Abbreviated title :

Bone Marrow Transplant

Publication date :

2023-02-25

ISSN :

1476-5365

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

Post-transplant cyclophosphamide (PTCy) is being increasingly used as graft-versus-host disease (GVHD) prophylaxis post allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients with acute myeloid leukemia ...
Show more >Post-transplant cyclophosphamide (PTCy) is being increasingly used as graft-versus-host disease (GVHD) prophylaxis post allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients with acute myeloid leukemia (AML) transplanted in first complete remission (CR1). However, results may differ in patients transplanted in CR2. We retrospectively evaluated transplant outcomes of adult AML patients transplanted between 2010–2019 from 9–10/10 human leukocyte antigen (HLA)-matched unrelated donor (UD) in CR2. In total, 127 patients were included (median age 45.5 years, 54% male). Median follow-up was 19.2 months. Conditioning was myeloablative (MAC) in 50.4% and the graft source was peripheral blood in 93.7% of the transplants. Incidence of acute (a)GVHD II-IV and III-IV was 26.2% and 9.2%. Two-year total and extensive chronic (c)GVHD were 34.3% and 13.8 %, respectively. Two-year non-relapse mortality (NRM), relapse incidence (RI), leukemia-free survival (LFS), overall survival (OS), and GVHD-free, relapse-free survival (GRFS) were 17.2%, 21.1%, 61.7, %, 65.2%, and 49.3%, respectively. Time from diagnosis to transplant (>18 months) was a favorable prognostic factor for RI, LFS, OS, and GRFS while favorable risk cytogenetics was a positive prognostic factor for OS. The patient’s age was a poor prognostic factor for NRM and cGVHD. Finally, the female-to-male combination and reduced intensity conditioning (RIC) were poor and favorable prognostic factors for cGVHD, respectively. We conclude that PTCy is an effective method for GVHD prophylaxis in AML patients undergoing allo-HCT in CR2 from UD.Show less >

Language :

Anglais

Audience :

Internationale

Popular science :

Non

Administrative institution(s) :

Université de Lille
Inserm
CHU Lille

Collections :

• Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286

Submission date :

2024-01-11T23:18:06Z
2024-03-04T14:23:45Z